CD274 and non-small cell lung carcinoma: Besides, pembrolizumab monotherapy significantly improved the survival over chemotherapy in treatment-naive advanced NSCLC patients with PD-L1 strong positive expression14, while nivolumab monotherapy failed to extend survival in the first-line trial15.